LU88198A1 - Agents de blocage neuromusculaires - Google Patents

Agents de blocage neuromusculaires Download PDF

Info

Publication number
LU88198A1
LU88198A1 LU88198A LU88198A LU88198A1 LU 88198 A1 LU88198 A1 LU 88198A1 LU 88198 A LU88198 A LU 88198A LU 88198 A LU88198 A LU 88198A LU 88198 A1 LU88198 A1 LU 88198A1
Authority
LU
Luxembourg
Prior art keywords
cis
salt
atracurium
physiologically acceptable
optical isomers
Prior art date
Application number
LU88198A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of LU88198A1 publication Critical patent/LU88198A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Semiconductor Lasers (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Led Devices (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Paper (AREA)

Claims (3)

1. - Sel de lR-cis,1'R-cis atracurium sensiblement exempt de ses autres isomères géométriques et optiques. 2. - Sel de lR-cis.1'R-cis atracurium suivant la revendication 1, en mélange avec moins de 5% p/p de ses autres isomères géométriques et optiques. 3. - Sel de IR-cis,1'R-cis atracurium suivant la revendication 1, en mélange avec moins de 2% p/p de ses autres isomères géométriques et optiques. 4. - Sel de lR-cis,I1R-cis atracurium physiologiquement acceptable suivant l'une quelconque des revendications précédentes. 5. - Mésylate ou bésylate de lR-cis,1'R-cis atracurium suivant la revendication 4. 6. - Sel de lR-cis,1'R-cis atracurium physiologiquement acceptable suivant la revendication 4, à utiliser en chirurgie ou thérapeutique médicale. 7. - Sel de lR-cis.1'R-cis atracurium physiologiquement acceptable suivant la revendication 6, pour induire le blocage neuromusculaire chez un animal. 8. - Utilisation d'un sel lR-cis,1'R-cis atracurium physiologiquement acceptable suivant la revendication 4 ou 5, pour la préparation d'un médicament pour induire le blocage neuromusculaire. 9. - Composition pharmaceutique comprenant un sel de lR-cis,1'R-cis atracurium physiologiquement acceptable suivant la revendication 4 ou 5, conjointement avec un excipient pharmaceutiquement acceptable. 10. - Composition pharmaceutique suivant la revendication 9, adaptée à l'administration par injection ou perfusion.
10.- Procédé de préparation d'un sel de lR-cis.l'R-cis atracurium suivant la revendication 1, qui comprend l'exposition d'un sel de 1R,1'R atracurium correspondant à l'effet de conditions ou réactants servant à opérer l'isolement de l'isomère lR-cis.1'R-cis des isomères géométriques correspondants contenus dans ce sel de IR,1'R atracurium.
12.- Procédé pour induire le blocage neuromusculaire chez un animal, qui comprend l'administration à cet animal, en quantité efficace pour le blocage neuromusculaire, d'un sel de lR-cis.l'R-cis atracurium physiologiquement acceptable sensiblement exempt de ses autres isomères géométriques et optiques.
LU88198A 1990-07-13 1992-12-09 Agents de blocage neuromusculaires LU88198A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909015473A GB9015473D0 (en) 1990-07-13 1990-07-13 Neuromuscular blocking agents
PCT/GB1991/001150 WO1992000965A1 (fr) 1990-07-13 1991-07-12 Agents de blocage neuromusculaire

Publications (1)

Publication Number Publication Date
LU88198A1 true LU88198A1 (fr) 1993-05-17

Family

ID=10679071

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88198A LU88198A1 (fr) 1990-07-13 1992-12-09 Agents de blocage neuromusculaires

Country Status (40)

Country Link
EP (1) EP0539470B1 (fr)
JP (3) JP2823356B2 (fr)
KR (1) KR0174284B1 (fr)
AT (1) ATE138369T1 (fr)
AU (2) AU8190491A (fr)
BE (1) BE1003407A3 (fr)
CA (1) CA2087104C (fr)
CH (1) CH683427A5 (fr)
CY (1) CY1985A (fr)
CZ (1) CZ284645B6 (fr)
DE (2) DE4191541T1 (fr)
DK (2) DK0539470T3 (fr)
ES (2) ES2083315B1 (fr)
FI (2) FI982342A0 (fr)
FR (1) FR2665701B1 (fr)
GB (2) GB9015473D0 (fr)
GE (1) GEP19981163B (fr)
GR (1) GR3020792T3 (fr)
HK (1) HK80196A (fr)
HU (2) HU218766B (fr)
IE (1) IE912440A1 (fr)
IL (1) IL98814A (fr)
IT (1) IT1249677B (fr)
LT (1) LT3317B (fr)
LU (1) LU88198A1 (fr)
LV (1) LV10432B (fr)
MX (1) MX9203220A (fr)
MY (1) MY113017A (fr)
NL (1) NL9120017A (fr)
NZ (1) NZ238964A (fr)
PA (1) PA8401801A1 (fr)
PL (1) PL167302B1 (fr)
PT (1) PT98306B (fr)
RU (1) RU2104005C1 (fr)
SA (1) SA91120073B1 (fr)
SE (1) SE9300052L (fr)
SK (1) SK279907B6 (fr)
UA (1) UA32536C2 (fr)
WO (1) WO1992000965A1 (fr)
ZA (1) ZA915468B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453510A (en) * 1990-07-13 1995-09-26 Burroughs Wellcome Co. Neuromuscular blocking agents
DE19535762A1 (de) * 1995-09-26 1997-03-27 Basf Ag Verfahren zur Racematspaltung
US5684154A (en) * 1996-02-16 1997-11-04 Abbott Laboratories Process for the preparation and isolation of atracurium besylate
CN1203061C (zh) * 1997-03-25 2005-05-25 艾弗拉药品公司 取代异喹啉类，其制备方法，药物组合物及其制药用途
BRPI0808272A2 (pt) 2007-03-08 2014-07-08 Chemagis Ltd "método para cromatograficamente separar o isômero 1r-cis, 1´r-cis de uma mistura de isômeros de (1r-1'r) - atracúrio, besilato de cisatracúrio e isômero 1r-cis, 1'r-cis do besilato de cisatracúrio"
EP2125743A1 (fr) * 2007-03-26 2009-12-02 Chemagis Ltd. Procédé de séparation de sels de (1r, 1'r)-atracurium
AU2008273724B2 (en) 2007-05-01 2013-05-23 Chemagis Ltd. Process for Producing Cisatracurium and Associated Intermediates
BRPI0809893A2 (pt) 2007-05-01 2014-09-30 Chemagis Ltd Processo para prepar um sal de (1r-cis) - [(3,4 - dimetoxifenil) metil] - 1, 2,3,4 - tetraidro - 6,7 - dimetoxi - 2 - metil - 2 - carboxietil - isoquinolínio"
AU2008264802A1 (en) * 2007-06-18 2008-12-24 Chemagis Ltd. (1R,1'R)-atracurium salts separation process
CN101337935B (zh) * 2007-07-06 2011-01-12 江苏恒瑞医药股份有限公司 一种用两相萃取法纯化苯磺酸阿曲库铵的方法
CN101337936B (zh) * 2007-07-06 2011-03-23 江苏恒瑞医药股份有限公司 一种用柱色谱法纯化苯磺酸阿曲库铵的方法
US8354537B2 (en) 2007-10-29 2013-01-15 Chemagis Ltd. R,R1-atracurium salts
IT1396543B1 (it) * 2008-07-16 2012-12-14 Farmabios Spa Processo per la purificazione di bloccanti neuromuscolari
WO2010128518A2 (fr) * 2009-05-04 2010-11-11 Gland Pharma Limited Nouveau procédé pour la préparation de bésylate de cisatracurium
CN107056700A (zh) * 2017-04-18 2017-08-18 哈尔滨医科大学 一种四氢异喹啉类化合物外消旋体的半量拆分法
CN112939862B (zh) * 2021-02-03 2023-01-10 江苏诚信药业有限公司 一种苯磺顺阿曲库铵杂质h的分离制备方法及其应用
CN115850169B (zh) * 2022-10-17 2025-04-04 上海医药集团(本溪)北方药业有限公司 苯磺顺阿曲库铵杂质及其中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004031A (en) * 1958-07-03 1961-10-10 Allen & Hauburys Ltd Diquaternary salts of papaverino esters
GB1579822A (en) * 1976-10-29 1980-11-26 Wellcome Found Tetrahydroisoquinolinium muscle relaxants
AU506657B2 (en) * 1975-12-10 1980-01-17 Wellcome Foundation Limited, The Isoquinoline derivatives
ES454090A1 (es) * 1976-12-09 1978-01-16 Wellcome Found Un metodo para preparar compuestos heterociclicos.
DE3328664A1 (de) * 1983-08-09 1985-02-21 Robert Bosch Gmbh, 7000 Stuttgart Zuckerziehmaschine
BG41897A1 (en) * 1985-07-19 1987-09-15 Ivanov Dichlormethylate of n, n'- 4, 10- dioxa- 3, 11- bis- tetrahydropapaverine and method for its preparation
US9524531B2 (en) 2011-05-09 2016-12-20 Microsoft Technology Licensing, Llc Extensibility features for electronic communications

Also Published As

Publication number Publication date
CZ284645B6 (cs) 1999-01-13
LV10432B (en) 1995-08-20
PL167302B1 (en) 1995-08-31
NZ238964A (en) 1992-06-25
IL98814A (en) 1995-12-08
GEP19981163B (en) 1998-07-06
FR2665701B1 (fr) 1995-03-03
GB2260763A (en) 1993-04-28
FI982342A7 (fi) 1998-10-28
KR0174284B1 (ko) 1999-02-18
HUT67613A (en) 1995-04-28
JPH10139763A (ja) 1998-05-26
DE4191541T1 (de) 1993-05-13
UA32536C2 (uk) 2001-02-15
EP0539470A1 (fr) 1993-05-05
AU8190491A (en) 1992-02-04
PT98306B (pt) 1999-01-29
MY113017A (en) 2001-11-30
HU211169A9 (en) 1995-11-28
JPH05508648A (ja) 1993-12-02
SK383392A3 (en) 1999-05-07
DK0539470T3 (da) 1996-08-05
FI103507B (fi) 1999-07-15
FR2665701A1 (fr) 1992-02-14
GB9224764D0 (en) 1993-02-03
MX9203220A (es) 1992-07-01
EP0539470B1 (fr) 1996-05-22
BE1003407A3 (fr) 1992-03-17
GR3020792T3 (en) 1996-11-30
WO1992000965A1 (fr) 1992-01-23
CY1985A (en) 1997-09-05
CZ383392A3 (en) 1994-02-16
RU2104005C1 (ru) 1998-02-10
JP3462165B2 (ja) 2003-11-05
PA8401801A1 (es) 1997-01-03
PL297606A1 (fr) 1992-07-13
CA2087104A1 (fr) 1992-01-14
DK149692D0 (da) 1992-12-14
SE9300052D0 (sv) 1993-01-12
IT1249677B (it) 1995-03-09
LV10432A (lv) 1995-02-20
ES2083315B1 (es) 1997-11-16
GB2260763B (en) 1994-01-05
ES2088009T3 (es) 1996-08-01
IL98814A0 (en) 1992-07-15
AU1134695A (en) 1995-03-30
SA91120073B1 (ar) 2002-10-26
ES2083315A1 (es) 1996-04-01
NL9120017A (nl) 1993-04-01
ATE138369T1 (de) 1996-06-15
AU687481B2 (en) 1998-02-26
DE69119768T2 (de) 1996-10-02
FI103507B1 (fi) 1999-07-15
IE912440A1 (en) 1992-01-15
ITRM910518A0 (it) 1991-07-12
ITRM910518A1 (it) 1993-01-12
FI982342L (fi) 1998-10-28
FI925894A0 (fi) 1992-12-28
FI982342A0 (fi) 1998-10-28
DK149692A (da) 1992-12-14
JP2823356B2 (ja) 1998-11-11
HK80196A (en) 1996-05-17
LTIP274A (en) 1994-10-25
FI925894L (fi) 1992-12-28
GB9015473D0 (en) 1990-08-29
HU9300052D0 (en) 1993-04-28
HU218766B (hu) 2000-11-28
CH683427A5 (fr) 1994-03-15
CA2087104C (fr) 1998-08-18
SE9300052L (sv) 1993-01-12
PT98306A (pt) 1992-06-30
JP2001058981A (ja) 2001-03-06
LT3317B (en) 1995-06-26
ZA915468B (en) 1993-03-31
SK279907B6 (sk) 1999-05-07
DE69119768D1 (de) 1996-06-27

Similar Documents

Publication Publication Date Title
LU88198A1 (fr) Agents de blocage neuromusculaires
Sparkes et al. Antinociceptive activity of morphine after injection of biogenic amines in the cerebral ventricles of the conscious rat
Marsden et al. A year's comparison of treatment of patients with Parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone
Castillo The neuromuscular blocking action of succinylcholine (diacetylcholine)
Chapman et al. Anticonvulsant action of a 1, 5‐benzodiazepine, clobazam, in reflex epilepsy
KR890001533A (ko) 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용
SK11596A3 (en) A composition for the therapy of undepressed women suffer from hypothalamic amenorrhea
Plotnikoff et al. Oxotremorine antagonism by prolyl-leucyl-glycine-amide administered by different routes and with several anticholinergics
RU93004869A (ru) Нервно-мышечный блокатор, его получение, фармацевтический состав и способ обеспечения нервно-мышечной блокады у животных
Morris et al. Pharmacokinetics of edrophonium in anephric and renal transplant patients
FR2375248A1 (fr) Nouveaux derives de sucres amines, leur procede de preparation et medicament les contenant
US4916125A (en) Method of treating migraine
US3439094A (en) Analgesic compositions containing namol xenyrate,caffeine and acetyl-rho-aminophenol
Nagatomo et al. Relationships between convulsive seizures and serum and brain concentrations of phenobarbital and zonisamide in mutant inbred strain EL mouse
Drance et al. Pilocarpine and Intraocular Pressure: Duration of Effectiveness of 4% and 8% Pilocarpine Instillation
KR910018348A (ko) 술포닐아미노치환 비시클로환계 히드록삼산 유도체
AU5456899A (en) Medicinal product and method for treatment and prevention of dyskinesia
Grewal et al. Mechanism of the antagonism of the hypotensive action of guanethidine by propranolol
US3824313A (en) Topical opthalmic composition and methods of use
Kalas et al. The effect of vasoactive antagonists in endetoxin shock
EP0132880A1 (fr) Compositions pharmaceutiques à base d'épinine ou un sel pharmaceutiquement acceptable
RU94027770A (ru) Препарат для профилактики и лечения гинекологических и послеродовых заболеваний самок сельскохозяйственных животных и способ его применения
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
US3026323A (en) Salts of tribasic acids
Nattero et al. Reserpine for migraine prophylaxis